메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

아태지역 사업자 4명 중 3명, "내년 경제 여건 개선 전망"… 허벌라이프 '아시아태평양 건강 및 경제 역량 인식 조사' 결과 발표

홍콩, 2025년 12월 30일 -- 아시아태평양 지역 사업자들은 향후 1년간 자신의 경제 여건이 개선될 것이라는 기대가 높은 것으로 나타났다. 비(非)사업자에 비해 경제와 건강을 스스로 관리할 수 있다는 인식도 뚜렷해, 삶 전반에 대한 자신감과 주도성이 두드러졌다는 분석이다. 건강 및 웰니스 뉴트리션 전문 글로벌 기업 허벌라이프(Herbalife)가 지난 17일 '2025 아시아태평양 건강 및 경제 역량 인식 조사' 결과를 발표했다. 지난 10월 실시된 '2025 아시아태평양 건강 및 경제 역량 인식 조사'는 호주, 홍콩, 인도네시아, 일본, 한국, 말레이시아, 필리핀, 싱가포르, 대만, 태국, 베트남 등 11개 국가에서 사업자 2,245명을 포함해 총 8,505명을 대상으로 진행됐다. 조사에서 '건강 역량'은 '자신의 신체적, 정신적, 정서적 웰빙 향상에 도움이 되는 결정을 내릴 수 있는 능력'으로, '경제 역량'은 '재정적 안정성을 높이는 능력'으로 정의했다. 조사에 따르면 아태 지역 사업자 응답자 가운데 74%는 향후 12개월 이내 경제적 여건이 개선될 것으로 내다보며, 같은 질문에 긍
- 노기식 기자
- 2025-12-30 16:11
Masa Draws the Sea Again

The Norwegian Refugee Council's Better Learning Programme, funded by Education Cannot Wait, delivers mental health and psychosocial support alongside education for children in Gaza. GAZA, Palestine, Dec. 30, 2025 -- In a tent in Deir al-Balah, Gaza, 12-year-old Masa carefully places her colored pencil on the page, tracing the curve of a wave. Her brown hair is pulled back in a ponytail, secured with two plastic barrettes. The sea she draws is calm and glimmering. In her real world, nothing is calm. But in this small act of creativity – in the rhythm of drawing a
- 김갑성 기자
- 2025-12-30 13:50
Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards

SHENZHEN, China, Dec. 30, 2025 -- On December 5, 2025, Dr. Lu Xianping, Founder, Chairman of Shenzhen Chipscreen Biosciences Co., Ltd, has been named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards. This recognition honors his outstanding contributions to advancing new-quality productive forces and driving innovation within the pharmaceutical industry. The award program, themed "Two Decades of Unwavering Strength, Forging Ahead in the New Era," celebrates entrepreneurs who shoulder new-era responsibilities and contribute significantl
- 김갑성 기자
- 2025-12-30 08:45
Bioelectric Toothbrush Offers New Approach with 6x Plaque Removal

[ 메디채널 김갑성 기자 ] Clinically validated microcurrent technology now available in the U.S. market SAN FRANCISCO, Dec. 29, 2025 -- Great Gums Inc. today announced the U.S. launch of its bioelectric toothbrush, a clinically validated oral care device that delivers safe microcurrents to remove plaque from hard-to-reach areas where traditional bristles cannot effectively clean. According to clinical studies, the bioelectric method demonstrated a sixfold improvement in plaque removal efficiency in deep, difficult-to-access regions of the mouth compared to traditional brushing.[
- 김갑성 기자
- 2025-12-29 21:00
HKSH Medical Group and Southern University of Science and Technology Collaborate for Medical and Medical Physics Training, Enhancing Medical Education and Research Innovation

HONG KONG, Dec. 29, 2025 -- HKSH Medical Group ("HKSH") and Southern University of Science and Technology ("SUSTech") officially signed a Memorandum of Understanding ("MOU") on 15 December 2025, a significant initiative to deepen collaboration between Hong Kong and the Chinese Mainland in the fields of medicine and medical physics. During the signing ceremony, Dr. Walton LI, Chief Executive Officer of HKSH Medical Group and Medical Superintendent of Hong Kong Sanatorium & Hospital, and Professor JIANG Hong, Party Secretary of SU
- 김갑성 기자
- 2025-12-29 16:12
Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities

SHANGHAI, Dec. 29, 2025 -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology platform that covers this end-to-end modality range, supporting programs from in vitro ADME assays through in vivo PK and efficacy studies. Adventures in DMPK: From Small Molecules and PROTACs to Peptides and Antibodies, the latest session in the Viva BioInsights webinar series, was presented by Dr. Justin Cu
- 김갑성 기자
- 2025-12-29 14:13
Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE

SUZHOU, China, Dec. 29, 2025 -- Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor) in combination with platinum-based chemotherapy with or without bevacizumab as first-line treatment of advanced cervical cancer (Study Number: JSKN033-202), has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). C
- 김갑성 기자
- 2025-12-29 13:52
Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy

TAIPEI and SAN DIEGO, Dec. 29, 2025 -- Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of cold tumor treatment, Senhwa Biosciences, Inc. (TPEx: 6492, hereafter "Senhwa"), today announced another major milestone. The Company's first-in-class investigational drug Pidnarulex (CX-5461) will be evaluated in combination with the globally recognized antibody-drug conjugate (ADC), Trastuzumab Deruxtecan (Enhertu®), in a Phase 1b clini
- 김갑성 기자
- 2025-12-29 10:24
Assure Healthcare Holdings Opens Second Clinic in Woodlands, Singapore

SINGAPORE, Dec. 29, 2025 -- Assure Healthcare Holdings, a subsidiary of SingWealth Holdings, today announced the official opening of its second clinic, Assure Family Clinic Woodlands. This expansion marks the next phase in the Group's mission to make quality and comprehensive healthcare more accessible to families and individuals. Located in the heart of Woodlands at 132 Marsiling Rise, the new clinic extends Assure Healthcare Holdings' footprint beyond its first location in Bukit Merah. The clinic will provide residents in northern Singapore with convenient access to g
- 김갑성 기자
- 2025-12-29 10:00
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 29, 2025 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. ("Lannacheng"). The two parties will leverage their respective resources and strengths to jointly advance the development of next-generation radionuclide drug conjugates (RDCs). Compared with conve
- 김갑성 기자
- 2025-12-29 09:58

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 16시 00분